# Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

> **NCT05935215** · PHASE3 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 50 (estimated)

## Conditions studied

- Atypical Hemolytic Uremic Syndrome

## Interventions

- **DRUG:** Iptacopan

## Key facts

- **NCT ID:** NCT05935215
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-28
- **Primary completion:** 2028-07-21
- **Final completion:** 2029-07-19
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05935215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05935215, "Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05935215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*